156 related articles for article (PubMed ID: 10695094)
1. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
Balgos AA; Rodriguez-Gomez G; Nasnas R; Mahasur AA; Margono BP; Tinoco-Favila JC; Sansores-Martinez RH; Hassan M; Beppo O; Wongsa A; Cukier A; Vargas F
Int J Clin Pract; 1999; 53(5):325-30. PubMed ID: 10695094
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
3. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of twice-daily amoxycillin/clavulanate ('Augmentin-Duo' 400/57) in mild to moderate lower respiratory tract infection in children.
Cook RC; Zachariah J; Cree F; Harrison HE
Br J Clin Pract; 1996; 50(3):125-8. PubMed ID: 8733329
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
[TBL] [Abstract][Full Text] [Related]
7. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of amoxycillin/clavulanate (Augmentin) twice daily versus three times daily in the treatment of acute otitis media in children. The Augmentin 454 Study Group.
Damrikarnlert L; Jauregui AC; Kzadri M
J Chemother; 2000 Feb; 12(1):79-87. PubMed ID: 10768519
[TBL] [Abstract][Full Text] [Related]
9. Ofloxacin in the treatment of lower respiratory tract infections: report of a prospective, comparative trial.
Khajotia RR; Vetter N; Harazin H
Clin Ther; 1991; 13(4):460-6. PubMed ID: 1933997
[TBL] [Abstract][Full Text] [Related]
10. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.
Paris R; Confalonieri M; Dal Negro R; Ligia GP; Mos L; Todisco T; Rastelli V; Perna G; Cepparulo M
J Chemother; 2008 Feb; 20(1):77-86. PubMed ID: 18343748
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
[TBL] [Abstract][Full Text] [Related]
13. Cefaclor af versus amoxycillin/clavulanate in acute bacterial exacerbations of chronic bronchitis: a randomised multicentre study.
Bandak SI; Bolzon LD; Turnak MR; Johns D; Henle SK; Allen BS
Int J Clin Pract; 1999 Dec; 53(8):578-83. PubMed ID: 10692750
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
15. Development of a twice daily dosing regimen of amoxicillin/clavulanate.
Bax R
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S118-21. PubMed ID: 17983732
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults.
Prabhudesai PP; Jain S; Keshvani A; Kulkarni KP
J Indian Med Assoc; 2011 Feb; 109(2):124-7. PubMed ID: 21888181
[TBL] [Abstract][Full Text] [Related]
17. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
18. Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice.
Bucher HC; Tschudi P; Young J; Périat P; Welge-Lüussen A; Züst H; Schindler C;
Arch Intern Med; 2003 Aug 11-25; 163(15):1793-8. PubMed ID: 12912714
[TBL] [Abstract][Full Text] [Related]
19. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia.
Higuera F; Hidalgo H; Feris J; Giguere G; Collins JJ
J Antimicrob Chemother; 1996 Mar; 37(3):555-64. PubMed ID: 9182112
[TBL] [Abstract][Full Text] [Related]
20. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
File TM; Jacobs MR; Poole MD; Wynne B;
Int J Antimicrob Agents; 2002 Oct; 20(4):235-47. PubMed ID: 12385678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
